U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Ruxolitinib

Last Revision: December 15, 2023.

Estimated reading time: 1 minute

CASRN: 941678-49-5

image 135263142 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of ruxolitinib during breastfeeding. Because ruxolitinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ruxolitinib therapy and for 2 weeks after the last dose for the oral tablets and for 4 weeks after the last dose for the topical cream.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Ruxolitinib

CAS Registry Number

941678-49-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500864PMID: 29999923

Views

Related information

Similar articles in PubMed

  • Review Baricitinib.[Drugs and Lactation Database (...]
    Review Baricitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ibrutinib.[Drugs and Lactation Database (...]
    Review Ibrutinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Tofacitinib.[Drugs and Lactation Database (...]
    Review Tofacitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Vemurafenib.[Drugs and Lactation Database (...]
    Review Vemurafenib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Abrocitinib.[Drugs and Lactation Database (...]
    Review Abrocitinib.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...